Subsequent IMC of a mixed-stage human NSCLC cohort showed a higher proportion of CD8+Ts were Ebo cells in patients with late-stage, versus early-stage, disease (p = 0.006), suggesting expansion with time and disease progression. Here, CD8A is linked to non-small cell lung carcinoma.